Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

243.45 -1.10 (-0.45%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

99 100 Next >

Beyond The Numbers: 10 Analysts Discuss Johnson & Johnson Stock ↗

September 23, 2025

Via Benzinga

The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now ↗

September 23, 2025

This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety?

Via The Motley Fool

Jim Cramer Says Trump Is Creating 'A Nightmare' For Kenvue As President Links Tylenol With Autism ↗

September 23, 2025

Jim Cramer says Trump creates a "nightmare" for Kenvue after linking Tylenol to autism. Learn why KVUE stock is plunging amid lawsuit fears.

Via Benzinga

Topics Government Lawsuit

Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check? ↗

September 23, 2025

Guggenheim’s upgrade and new data on J&J’s experimental depression drug helped steady sentiment, even as investors weighed political scrutiny and ongoing litigation risks.

Via Stocktwits

Topics Government

Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish ↗

September 22, 2025

Via Stocktwits

Topics Government

U.S. Government Shutdown Looms: A Guide for Investors Navigating Political and Economic Uncertainty

September 22, 2025

As the perennial specter of a U.S. government shutdown once again casts a shadow over Washington, D.C., financial markets are bracing for potential turbulence. The failure of Congress to agree on...

Via MarketMinute

Topics Bonds Economy

Kenvue Stock Sinks To Record Low As Trump To Reportedly Link Tylenol Use To Autism ↗

September 22, 2025

The latest controversy poses a new reputational challenge for Kenvue, which was spun out of Johnson & Johnson in 2023.

Via Talk Markets

Topics Government

The Enduring Appeal of Dividend Aristocrats: A Beacon of Stability in Turbulent Markets

September 22, 2025

In an era marked by fluctuating interest rates, geopolitical uncertainties, and shifting economic landscapes, a select group of companies known as "Dividend Aristocrats" continues to shine as pillars...

Via MarketMinute

Topics ETFs Economy Energy

The Unyielding Power of Dividends: A Blueprint for Enduring Wealth

September 22, 2025

In an era of fluctuating financial markets and evolving economic landscapes, the allure of dividend-paying stocks as a cornerstone for building long-term wealth remains as potent as ever. As investors...

Via MarketMinute

Topics Retirement Supply Chain

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance

September 22, 2025

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Kenvue, J&J Retail Traders Cautious As US Health Officials Reportedly Plan To Announce Tylenol Links To Autism ↗

September 22, 2025

Tylenol is one of the most common medicines for reducing pain and fever, and a major product for Kenvue.

Via Stocktwits

Topics Government

Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years? ↗

September 21, 2025

The trillion-dollar club will probably need to make room for at least one Dividend King in the coming years.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Ben & Jerry's Co-Founder Resigns In Protest As Politics Continue To Influence Corporate Exits ↗

September 20, 2025

Jerry Greenfield, of Ben & Jerry's fame, didn't resign over personal controversy—he quit because his company stopped being political enough.

Via Benzinga

What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill ↗

September 20, 2025

A high yield is only one part of the story when it comes to picking dividend stocks.

Via The Motley Fool

Topics Intellectual Property

Johnson & Johnson Confronts the End of its Talc Legacy with Multi-Billion Dollar Settlements

September 19, 2025

Johnson & Johnson (NYSE: JNJ) is navigating a critical juncture in its protracted legal battle over talc-based baby powder. The healthcare behemoth has announced a tentative $700 million settlement...

Via MarketMinute

Topics Bankruptcy Death Lawsuit

P&G's Q3 2025: Sales Miss Overshadows Earnings Beat Amidst Global Headwinds

September 19, 2025

Procter & Gamble (NYSE: PG) recently disclosed its fiscal third-quarter 2025 results, presenting a nuanced financial picture that has stirred investor sentiment. While the consumer goods titan managed...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era

September 19, 2025

Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet...

Via MarketMinute

Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients ↗

September 19, 2025

Johnson & Johnson's Tecvayli-Darzalex regimen showed 100% response rates and high MRD negativity in newly diagnosed multiple myeloma patients.

Via Benzinga

Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J? ↗

September 19, 2025

The company is looking to take on Johnson & Johnson in treating patients with a precursor to multiple myeloma.

Via Investor's Business Daily

Recent Report Shows That Rep. Thomas Kean Bought Up to $45K Worth of Amcor Stock ↗

September 19, 2025

Via Benzinga

8 Dividend Growth Stocks Every Investor Should Consider ↗

September 19, 2025

These dividend powerhouses compound wealth through decades of consecutive increases and sustainable payout ratios.

Via The Motley Fool

Topics Artificial Intelligence Economy

Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday ↗

September 18, 2025

Nanobiotix reported melanoma study data showing JNJ-1900 delivered 47.4% response rate, 78.9% disease control, and 14.6 months survival.

Via Benzinga

Intuitive Surgical: A Steady Hand in a Storm of AI Hype?

September 18, 2025

In a financial landscape increasingly dominated by the exhilarating, often volatile, narrative of artificial intelligence, Intuitive Surgical (NASDAQ: ISRG) stands as a testament to steady, fundamental...

Via MarketMinute

Topics Artificial Intelligence Supply Chain

Federal Reserve Navigates Stagflationary Headwinds with Dovish Pivot

September 18, 2025

Washington D.C. - The U.S. Federal Reserve finds itself at a critical juncture, facing an economic environment that is increasingly raising the specter of "stagflation" – a challenging combination of...

Via MarketMinute

Topics Economy Supply Chain World Trade

What the Options Market Tells Us About Johnson & Johnson ↗

September 18, 2025

Via Benzinga

The Specter of Stagflation: Is the Economy Headed for Stagnant Growth and High Inflation?

September 17, 2025

The U.S. Federal Reserve’s recent decision to cut interest rates has sent a tremor of concern through financial markets, sparking fears of a potential return to stagflation—an economic phenomenon...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials ↗

September 17, 2025

Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Johnson & Johnson (NY:JNJ)

All News about Johnson & Johnson

Starting at $3.75/week.

Subscribe Today